Abstract
Over the last two decades, a number of protein-protein interactions (PPIs) have been targeted by the pharmaceutical industry. Pharma as a whole has historically considered PPIs to be undruggable or at the very least high-risk targets, and the relative lack of success in modulating PPIs with small molecules has done little to change this prevailing view. However, many compounds are now in clinical trials, and the experiences of the last 20 years have at the very least led to improved understanding of how to approach these challenging targets. This chapter discusses some of the issues that PPIs present as targets for small molecule modulation, with emphasis on the structural characteristics of PPIs in general, and also of classes of PPIs that share specific attributes. Grouping PPIs by structural class produces a clearer picture of both the characteristics of optimized small molecules, and the relative merits and drawbacks of various PPIs as drug targets. Within this framework, much of the past work in the PPI area is summarized through capsule descriptions of efforts directed against individual targets. Some contributors to individual successes and failures, and some insights gained from the many avenues of research followed within the PPI field are put forward. Themes of the importance of understanding the structural basis of mechanism of action and of structural support for drug discovery emerge, and guidelines for future study are offered.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Hopkins AL, Groom CR (2002) The druggable genome. Nat Rev Drug Discov 1:727–730
Russ AP, Lampel S (2006) The druggable genome: an update. Drug Disc Today 10:1607–1610
Overington JP, Al-Lazikani B, Hopkins AL (2008) How many drug targets are there? Nat Rev Drug Discov 5:993–996
Grant A, Lee D, Orengo C (2004) Progress towards mapping the universe of protein folds. Genome Biol 5:107
Kunin V, Cases I, Enrigh E, de Lorenzo V, Ouzounis CA (2003) Myriads of protein families, and still counting. Genome Biol 4:401
Vitkup D, Melamud E, Moult J, Sander C (2001) Completeness in structural genomics. Nat Struct Biol 8:559–566
Stumpf M, Thorne T, de Silva ERS et al (2008) Estimating the size of the human interactome. Proc Natl Acad Sci USA 105:6959–6964
Ideker T, Sharan R (2008) Protein networks in disease. Genome Res 18:644–652
Strong M, Eisenberg D (2007) The protein network as a tool for finding novel drug targets. Prog Drug Res 64:191–215
Komurov K, White M (2007) Revealing static and dynamic modular architecture of the eukaryotic protein interaction network. Mol Syst Biol 3:110
Aggarwal S (2009) What’s fueling the biotech engine – 2008. Nat Rev Immunol 11:987–993
Toogood PL (2002) Inhibition of protein-protein association by small-molecules: approaches and progress. J Med Chem 45:1543–1558
Chene P (2006) Drugs targeting protein-protein interactions. ChemMedChem 1:400–411
Whitty A, Kumaravel G (2006) Between a rock and a hard place? Nat Chem Biol 2:112–118
Arkin MR, Wells JA (2004) Small-molecule inhibitors of protein-protein interactions: progressing towards the dream. Nat Rev Drug Discov 3:301–317
Wells JA, McClendon CL (2007) Reaching for high-hanging fruit in drug discovery at protein-protein interfaces. Nature 450:1001–1009
Fischer PM (2005) Protein-protein interactions in drug discovery. Drug Des Rev Online 2:179–207
Berg T (2008) Small-molecule inhibitors of protein-protein interactions. Curr Opin Drug Discov Dev 11:666–674
Fry DC (2008) Drug-like inhibitors of protein-protein interactions: a structural examination of effective protein mimicry. Curr Protein Pept Sci 9:240–247
Stites WE (1997) Protein-protein interactions: interface structure, binding thermodynamics, and mutational analysis. Chem Rev 97:1233–1250
Bogan AA, Thorn KS (1998) Anatomy of hot spots in protein interfaces. J Mol Biol 280:1–14
Young L, Jernigan RL, Covell DG (1994) A role for surface hydrophobicity in protein-protein recognition. Protein Sci 3:717–729
Lo Conte L, Chothia C, Janin J (1999) The atomic structure of protein-protein recognition sites. J Mol Biol 285:2177–219824
Archakov AI, Govorun VM, Dubanov AV et al (2003) Protein-protein interactions as a target for drugs in proteomics. Proteomics 3:380–391
Keskin O, Gursoy A, Ma B, Nussinov R (2008) Principles of protein-protein interactions: what are the preferred ways for proteins to interact? Chem Rev 108:1225–1244
Tsai CJ, Lin SL, Wolfson HJ, Nissinov R (1997) Studies of protein-protein interfaces: a statistical analysis of the hydrophobic effect. Protein Sci 6:53–64
Jones S, Thornton JM (1996) Principles of protein-protein interactions. Proc Natl Acad Sci USA 93:13–20
Jones S, Thornton JM (1997) Analysis of protein-protein interaction sites using surface patches. J Mol Biol 272:121–132
Argos P (1988) An investigation of protein subunit and domain interfaces. Protein Eng 2:101–113
Janin J, Miller S, Chothia C (1988) Surface, subunit interfaces and interior of oligomeric proteins. J Mol Biol 204:155–164
Bordner AJ, Abagyan R (2005) Statistical analysis and prediction of protein-protein interfaces. Proteins 60:353–366
Kufareva I, Budagyan L, Raush E et al (2007) PIER: protein interface recognition for structural proteomics. Proteins 67:400–417
Hu Z, Ma B, Wolfson H, Nussinov R (2000) Conservation of polar residues as hot spots at protein interfaces. Proteins 39:331–342
Fauchere JL, Pliska VE (1983) Hydrophobic parameters of amino-acid side-chains from the partitioning of N-acetyl-amino-acid amide. Eur J Med Chem 18:369–375
Radzicka A, Wolfenden R (1988) Comparing the polarities of the amino acids: side-chain distribution coefficients between the vapor phase, cyclohexane, 1-octanol, and neutral aqueous solution. Biochemistry 27:1664–1670
Takano K, Yutani K (2001) A new scale for side-chain contribution to protein stability based on the empirical stability analysis of mutant proteins. Protein Eng 14:525–528
Clackson T, Wells JA (1995) A hot spot of binding energy in a hormone-receptor interface. Science 267:383–386
Wells JA (1991) Systematic mutational analyses of protein-protein interfaces. Methods Enzymol 202:390–411
Atwell S, Ultsch M, de Vos AM, Wells JA (1997) Structural plasticity in a remodeled protein-protein interface. Science 278:1125–1128
Jonsson Z, Podust V, Podust L, Hubscher U (1995) Tyrosine 114 is essential for the trimeric structure and the functional activities of human proliferating cell nuclear antigen. EMBO J 14:5745–5751
Sattler M, Liang H, Nettesheim D et al (1997) Structure of Bcl-xL-Bak peptide complex: recognition between regulators of apoptosis. Science 275:983–986
Hajduk PJ, Huth JR, Fesik SW (2005) Druggability indices for protein targets derived from NMR-based screening data. J Med Chem 48:2518–2525
Kozakov D, Hall DR, Chuang G et al (2011) Structural conservation of druggable hot spots in protein–protein interfaces. Proc Natl Acad Sci USA 108:13528–13535
DeLano WL (2002) Unraveling hot spots in binding interfaces: progress and challenges. Curr Opin Struct Biol 12:14–20
Ma B, Elkayam T, Wolfson H, Nussinov R (2003) Protein-protein interactions: structurally conserved residues distinguish between protein binding sites and exposed protein surfaces. Proc Natl Acad Sci USA 100:5772–5777
Sundberg EJ, Mariuzza RA (2000) Luxury accommodations: the expanding role of structural plasticity in protein-protein interactions. Structure 8:R137–R142
Morrison KL, Weiss GA (2001) Combinatorial alanine scanning. Curr Opin Chem Biol 5:302–307
Sidhu SS, Fairbrother WJ, Deshayes K (2003) Exploring protein-protein interactions with phage display: discovery of peptidic antagonists of IGF-1 function. Chembiochem 4:14–25
Deshayes K (2005) Exploring protein-protein interactions using peptide libraries displayed on phage. In: Sidhu SS (ed) Phage display in biotechnology and drug discovery. CRC Press, Boca Raton
Hajduk PJ, Huth JR, Tse C (2005) Predicting protein druggability. Drug Discov Today 10:1675–1682
Burgoyne MJ, Jackson RM (2006) Predicting protein interaction sites: binding hot-spots in protein-protein and protein-ligand interfaces. Bioinformatics 22:1335–1342
Sugaya N, Furuya T (2011) Dr. PIAS: an integrative system for assessing the druggability of protein-protein interactions. BMC Bioinformatics 12:50
Perot S, Sperandio O, Miteva MA, Camproux AC, Villoutriex BO (2010) Druggable pockets and binding site centric chemical space: a paradigm shift in drug discovery. Drug Discov Today 15:656–667
Fuller JC, Burgoyne MJ, Jackson RM (2009) Predicting druggable binding sites at the protein-protein interface. Drug Discov Today 14:155–161
Hopkins A, Groom C, Alex A (2004) Ligand efficiency: a useful metric for lead selection. Drug Discov Today 9:430–431
Abad-Zapatero C, Metz JT (2005) Ligand efficiency indices as guideposts for drug discovery. Drug Discov Today 10:464–469
Higuerelo AP, Schreyer A, Bickerton GRJ et al (2009) Atomic interactions and profile of small-molecules disrupting protein-protein interfaces: the TIMBAL database. Chem Biol Drug Des 74:457–467
Lipinski C, Lombardo F, Dominy BW, Feeney PJ (1997) Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 23:3–25
Clark DE (1999) Rapid calculation of polar molecular surface area and its application to the prediction of transport phenomena. 1. Prediction of intestinal absorption. J Pharm Sci 88:807–814
Johnson TW, Dress KR, Edwards M (2009) Using the Golden Triangle to optimize clearance and oral absorption. Bioorg Med Chem Lett 19:5560–5564
Morelli X, Bourgeas R, Roche P (2011) Chemical and structural lessons from recent successes in protein-protein interaction inhibition (2P2I). Curr Opin Chem Biol 15:475–481
Reynès C, Host H, Camproux A et al (2010) Designing focused chemical libraries enriched in protein-protein interaction inhibitors using machine-learning methods. PLoS Comput Biol 6:e1000695
Neugebauer A, Hartmann RW, Klein CD (2007) Prediction of protein-protein interaction inhibitors by chemoinformatics and machine learning methods. J Med Chem 50:4665–4668
Oprea TI, Davis AM, Teague SJ, Leeson PD (2001) Is there a difference between leads and drugs? A historical perspective. J Chem Inf Model 41:1308–1315
Rishton GM (2003) Nonleadlikeness and leadlikeness in biochemical screening. Drug Discov Today 8:86–96
Teague SJ, Davis AM, Leeson PD, Oprea TI (1999) The design of leadlike combinatorial libraries. Angew Chem Int Ed Engl 38:3743–3748
Veber DF, Johnson SR, Cheng H-Y et al (2002) Molecular properties that influence the oral bioavailability of drug candidates. J Med Chem 45:2615–2623
Bergström CAS, Strafford M, Lazarova L et al (2003) Absorption classification of oral drugs based on molecular surface properties. J Med Chem 46:558–570
Hou TJ, Wang JM, Zhang W et al (2006) Recent advances in computational prediction of drug absorption and permeability in drug discovery. Curr Med Chem 13:2653–2667
Hou T, Wang J, Zhang W, Xu X (2007) ADME evaluation in drug discovery. 6. Can oral bioavailability in humans be effectively predicted by simple molecular property-based rules? J Chem Inf Model 47:460–463
Alex A, Millan DS, Perez M et al (2011) Intramolecular hydrogen bonding to improve membrane permeability and absorption in beyond rule of five chemical space. MedChemComm 2:669–674
Paolini GV, van Shepland RHB, Hoorn WP et al (2006) Global mapping of pharmacological space. Nat Biotechnol 24:805–815
Leeson PD, Springthorpe B (2007) The influence of drug-like concepts on decision-making in medicinal chemistry. Nat Rev Drug Discov 6:881–890
Wenlock MC, Austin RP, Barton P et al (2003) A comparison of physiochemical property profiles of development and marketed oral drugs. J Med Chem 46:1250–1256
Walters WP, Green J, Weiss JR, Murcko MA (2011) What do medicinal chemists actually make? A 50-year retrospective. J Med Chem 54:6405–6416
Leeson PD, Davis AM (2004) Time-related differences in the physical property profiles of oral drugs. J Med Chem 47:6338–6348
Proudfoot JR (2005) The evolution of synthetic oral drug properties. Bioorg Med Chem Lett 15:1087–1090
Blake JF (2005) Identification and evaluation of molecular properties related to preclinical optimization and clinical fate. Med Chem 1:649–655
Gill AL, Verdonk M, Boyle RG, Taylor R (2007) A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem 7:1408–1422
Bergström CAS, Wassvik CM, Johansson K, Hubatsch I (2007) Poorly soluble marketed drugs display solvation limited solubility. J Med Chem 50:5858–5862
Hawkins MJ, Soon-Shiong P, Desai N (2008) Protein nanoparticles as drug carriers in clinical medicine. Adv Drug Deliv Rev 60:1000–1017
Vintinoiu A, Leroux JC (2008) Organogels and their use in drug delivery: a review. J Control Release 125:179–192
Gupta S, Moulik SP (2008) Biocompatible microemulsions and their prospective uses in drug delivery. J Pharm Sci 97:22–45
Cheng Y, Xu Z, Ma M, Xu T (2008) Dendrimers as drug carriers: applications in different routes of drug administration. J Pharm Sci 97:123–143
Drummond DC, Noble CO, Hayes ME et al (2008) Pharmacokinetics and in vivo drug release rates in liposomal nanocarrier development. J Pharm Sci 97:4696–4740
Breitenbach J (2002) Melt extrusion: from process to drug delivery technology. Eur J Pharm Biopharm 54:107–117
DeLano WL, Ultsch MH, deVos AM, Wells JA (2000) Convergent solutions to binding at a protein-protein interface. Science 287:1279–1283
Eyrisch S, Helms V (2007) Transient pockets on protein surfaces involved in protein-protein interaction. J Med Chem 50:3457–3464
Ma B, Shatsky M, Wolfson HJ, Nussinov R (2002) Multiple diverse ligands binding at a single protein site: a matter of preexisting populations. Protein Sci 11:184–197
Teague S (2003) Implications of protein flexibility for drug discovery. Nat Rev Drug Discov 2:527–541
Kortemme T, Kim DE, Baker D (2004) Computational alanine scanning of protein-protein interfaces. Sci Signal 219:l2
McGovern SL, Caselli E, Grigorieff N, Shoichet BK (2002) A common mechanism underlying promiscuous inhibitors from virtual and high-throughput screening. J Med Chem 45:1712–1722
Seidler J, McGovern SL, Dornan TL, Shoichet BK (2003) Identification and prediction of promiscuous aggregating inhibitors among known drugs. J Med Chem 46:4477–4786
Lebowicz J, Lewis MS, Schuck P (2009) Modern analytical ultracentrifugation in protein science: a tutorial review. Protein Sci 11:2067–2079
Arkin M, Lear JD (2001) A new data analysis method to determine binding constants of small-molecules to proteins using equilibrium analytical ultracentrifugation with absorption optics. Anal Biochem 299:98–107
Philo JS (2000) Sedimentation equilibrium analysis of mixed associations using numerical constraints to impose mass or signal conservation. Methods Enzymol 321:100–120
Leavitt S, Freire E (2001) Direct measurement of protein binding energetics by isothermal titration calorimetry. Curr Opin Struct Biol 11:560–566
Lewis EA, Murphy KP (2005) Isothermal titration calorimetry. Methods Mol Biol 305:1–15
Pattnaik P (2000) Surface plasmon resonance. Applications in understanding receptor-ligand interaction. Appl Biochem Biotechol 126:79–92
Cooper M, Mayr LM, Rich RL, Myszka DG (2011) The revolution of real-time, label-free biosensor applications. In: Cooper M, Mayr LM (eds) Label-free technologies for drug discovery. Wiley, New York
Shuker SB, Hajduk PJ, Meadows RP, Fesik SW (1996) Discovering high-affinity ligands for proteins: SAR by NMR. Science 274:1531–1534
Hajduk PJ, Greer J (2007) A decade of fragment-based drug design: strategic advances and lessons learned. Nat Rev Drug Discov 6:211–219
Congreve M, Chessari G, Tisi D, Woodhead AJ (2008) Recent developments in fragment-based drug discovery. J Med Chem 51:3661–3680
Sun C, Petros AM, Hajduk PJ (2011) Fragment-based lead discovery: challenges and opportunities. J Comput Aided Mol Des 25:607–610
Coyne AG, Scott DE, Abell C (2010) Drugging challenging targets using fragment-based approaches. Curr Opin Chem Biol 14:299–307
Hämäläinen MD, Zhukov A, Ivarsson M et al (2008) Label-free primary screening and affinity ranking of fragment libraries using parallel analysis of protein panels. J Biomol Screen 13:202–209
Pellecchia M, Bertini I, Cowburn D et al (2008) Perspectives on NMR in drug discovery: a technique comes of age. Nat Rev Drug Discov 7:738–745
Navratilova I, Hopkins AL (2010) Fragment screening by surface plasmon resonance. ACS Med Chem Lett 1:44–48
Neumann T, Junker HD, Schmidt K, Sekul R (2007) SPR-based fragment screening: advantages and applications. Curr Top Med Chem 7:1630–1642
Nienaber VL, Richardson PL, Klighofer V et al (2000) Discovering novel ligands for macromolecules using X-ray crystallographic screening. Nat Biotechnol 18:1105–1108
Davies DR, Begley DW, Hartley RC et al (2011) Predicting the success of fragment screening by X-ray crystallography. Methods Enzymol 493:91–114
Jhoti H, Cleasby A, Verdonk M, Williams G (2008) Fragment-based screening using X-ray crystallography and NMR spectroscopy. Curr Opin Chem Biol 11:485–493
Hajduk PK, Gerfin T, Boehlen JM et al (1999) High-throughput nuclear magnetic resonance-based screening. J Med Chem 42:2315–2317
Dalvit C, Flocco M, Knapp S et al (2002) High-throughput NMR-based screening with competition binding experiments. J Am Chem Soc 124:7702–7709
Hajduk PJ, Burns DJ (2002) Integration of NMR and high-throughput screening. Comb Chem High Throughput Screen 6:613–621
Blundell TL, Jhoti H, Abell C (2002) High-throughput crystallography for lead discovery in drug design. Nat Rev Drug Discov 1:45–54
Blundell TL, Patel S (2004) High-throughput X-ray crystallography for drug discovery. Curr Opin Pharmacol 4:490–496
Köppen H (2009) Virtual screening – what does it give us? Curr Opin Drug Discov Dev 12:397–407
Cavasotto CN, Orry AJW (2007) Ligand docking and structure-based virtual screening in drug discovery. Curr Opin Med Chem 7:1006–1014
Betzi S, Restouin A, Opi S et al (2007) Protein–protein interaction inhibition (2P2I) combining high throughput and virtual screening: application to the HIV-1 Nef protein. Proc Natl Acad Sci USA 104:19256–19261
Casey FP, Pihan E, Shields DC (2009) Discovery of small-molecule inhibitors of protein-protein interactions using combined ligand and target score normalization. J Med Chem 49:2708–2717
Sandrini S (2005) Use of IL-2 receptor antagonists to reduce delayed graft function following renal transplantation: a review. Clin Transplant 19:705–710
Brandhuber BJ, Boone T, Kenney WC, McKay DB (1987) Three-dimensional structure of interleukin-2. Science 238:1707–1709
Sauve K, Nachman M, Spence C et al (1991) Localization in human interleukin 2 of the binding site to the α chain (p55) of the interleukin 2 receptor. Proc Natl Acad Sci USA 88:4636–4640
Tilley JW, Chen L, Fry DC et al (1997) Identification of a small-molecule inhibitor of the IL-2/IL-2Rα receptor interaction which binds to IL-2. J Am Chem Soc 119:7589–7590
Erlanson DA, Wells JA, Braisted AC (2004) Tethering: fragment-based drug discovery. Annu Rev Biophys 33:199–223
Hyde J, Braisted AC, Randal M, Arkin MR (2003) Discovery and characterization of cooperative ligand binding in the adaptive region of interleukin-2. Biochemistry 42:6475–6483
Raimundo BC, Oslob JD, Braisted AC et al (2004) Integrating fragment assembly and biophysical methods in the chemical advancement of small-molecule antagonists of IL-2: an approach for inhibiting protein-protein interactions. J Med Chem 47:3111–3130
Thanos CD, DeLano WL, Wells JA (2006) Hot-spot mimicry of a cytokine receptor by a small-molecule. Proc Natl Acad Sci USA 103:15422–15427
Rickert M, Wang X, Boulanger MJ et al (2005) The structure of interleukin-2 complexed with its alpha receptor. Science 308:1477–1480
Arkin MR, Randal M, DeLano WL et al (2003) Binding of small-molecules to an adaptive protein-protein interface. Proc Natl Acad Sci USA 100:1603–1608
Siddiqui MA, Perry CM (2006) Human papillomavirus quadrivalent (types 6, 11, 16, 18) recombinant vaccine (Gardasil). Drugs 66:1263–1271
Monie A, Hung CF, Roden R, Wu TC (2008) Cervarix: a vaccine for the prevention of HPV 16, 18-associated cervical cancer. Biologics 2:97–105
Hebner CM, Laimins LA (2006) Human papillomaviruses: basic mechanisms of pathogenesis and oncogenicity. Rev Med Virol 16:83–97
White PW, Faucher AM, Goudreau N (2011) Small-molecule inhibitors of the human papillomavirus E1–E2 interaction. Curr Top Microbiol Immunol 348:61–88
Yoakim C, Ogilvie WW, Goudreau N et al (2003) Discovery of the first series of inhibitors of human papilloma virus type 11: inhibition of the assembly of the E1-E2 Origin DNA complex. Bioorg Med Chem Lett 13:2539–2541
White PW, Titolo S, Brault K et al (2003) Inhibition of human papillomavirus DNA replication by small-molecule antagonists of the E1-E1 protein interaction. J Biol Chem 278:26765–26772
Wang Y, Coulombe R, Cameron DR et al (2004) Crystal structure of the E2 transactivation domain of human papillomavirus type 11 bound to a protein interaction inhibitor. J Biol Chem 279:6976–6985
Goudreau N, Cameron DR, Deziel R et al (2007) Optimization and determination of the absolute configuration of a series of potent inhibitors of human papillomavirus type-11 E1-E2 protein-protein interaction: a combined medicinal chemistry, NMR and computational chemistry approach. Bioorg Med Chem 15:2690–2700
White PW, Faucher AM, Goudreau N (2011) Small-molecule inhibitors of the human papillomavirus E1-E2 interaction. In: Vassilev L, Fry D (eds) Small-molecule inhibitors of protein-protein interactions. Springer, Berlin
Antson AA, Burns JE, Moroz OV et al (2000) Structure of the intact transactivation domain of the human papillomavirus E2 protein. Nature 403:805–809
Harris SF, Botchan MR (1999) Crystal structure of the human papillomavirus type 18 E2 activation domain. Science 284:1673–1677
Abbate E, Berger JM, Botchan MR (2004) The X-ray structure of the papillomavirus helicase in complex with its molecular matchmaker E2. Genes Dev 18:1981–1996
Mosyak L, Zhang Y, Glasfeld E et al (2000) The bacterial cell-division protein ZipA and its interaction with an FtsZ fragment revealed by X-ray crystallography. EMBO J 19:3179–3191
Tsao DHH, Sutherland AG, Jennings LD et al (2006) Discovery of novel inhibitors of the ZipA/FtsZ complex by NMR fragment screening coupled with structure-based design. Bioorg Med Chem 14:7953–7961
Jennings LD, Foreman KW, Rush TS et al (2004) Combinatorial synthesis of substituted 3-(2-indolyl)piperidines and 2-phenyl indoles as inhibitors of ZipA-FtsZ interaction. Bioorg Med Chem 12:5115–5131
Kenny CH, Ding W, Kelleher K et al (2003) Development of a fluorescence polarization assay to screen for inhibitors of the FtsZ/ZipA interaction. Anal Biochem 323:224–233
Rush TS, Grant JA, Mosyak L, Nicholls A (2005) A shape-based 3-D scaffold hopping method and its application to a bacterial protein-protein interaction. J Med Chem 48:1489–1495
Shangary S, Wang S (2009) Small-molecule inhibitors of the MDM2-p53 protein-protein interaction to reactivate p53 function: a novel approach for cancer therapy. Annu Rev Pharmacol Toxicol 49:223–241
Kussie PH, Gorina S, Marechal V et al (1996) Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain. Science 274:948–953
Lin J, Chen J, Elenbaas B, Levine AJ (1994) Several hydrophobic amino acids in the p53 amino-terminal domain are required for transcriptional activation, binding to mdm-2 and the adenovirus 5 E1B 55-kD protein. Genes Dev 8:1235–1246
Picksley SM, Vojtesek B, Sparks A, Lane DP (1994) Immunochemical analysis of the interaction of p53 with MDM2-fine mapping of the MDM2 binding site on p53 using synthetic peptides. Oncogene 9:2523–2529
Vassilev LT, Vu BT, Graves B et al (2004) In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 303:844–848
Grasberger BL, Lu T, Schubert C et al (2005) Discovery and cocrystal structure of benzodiazapinedione HDM2 antagonists that activate p53 in cells. J Med Chem 48:909–912
Allen JG, Bourbeau MP, Wohlhieter GE et al (2009) Discovery and optimization of chromenotriazolopyrimidines as potent inhibitors of the mouse double minute 2-tumor protein 53 protein-protein interaction. J Med Chem 52:7044–7053
Demma M, Maxwell E, Ramos R et al (2010) SCH529074, a small-molecule activator of mutant p53, which binds p53 DNA binding domain (DBD), restores growth-suppressive function to mutant p53 and interrupts HDM2-mediated ubiquitination of wild type p53. J Biol Chem 285:10198–10212
Yin H, Lee GI, Park HS et al (2005) Terphenyl-based helical mimetics that disrupt the p53/HDM2 interaction. Angew Chem Int Ed Engl 44:2704–2707
Stoll R, Renner C, Hansen S et al (2001) Chalcone derivatives antagonize interactions between the human oncoprotein MDM2 and p53. Biochemistry 40:336–344
Lu Y, Nikolovska-Coleska Z, Fang X et al (2006) Discovery of a nanomolar inhibitor of the human murine double minute 2 (MDM2)-p53 interaction through an integrated, virtual database screening strategy. J Med Chem 49:3759–3762
Bowman AL, Nikolovska-Coleska Z, Zhong H et al (2007) Small-molecule inhibitors of the MDM2-p53 interaction discovered by ensemble-based receptor models. J Am Chem Soc 129:12809–12814
Rothweiler U, Czarna A, Krajewski M et al (2008) Isoquinolin-1-one inhibitors of the MDM2-p53 interaction. ChemMedChem 3:1118–1128
Fry DC, Graves B, Vassilev LT (2005) Development of E3-substrate (MDM2-p53)-binding inhibitors: structural aspects. Methods Enzymol 399:622–633
Ding K, Lu Y, Nikolovska-Coleska Z et al (2006) Structure-based design of spire-oxindoles as potent, specific small-molecule inhibitors of the MDM2-p53 interaction. J Med Chem 49:3432–3435
Boettcher A, Buschmann N, Furet P et al (2008) 3-Imidazolylindoles for treatment of proliferative diseases and their preparation. PCT Int Appl WO2008119741
Popowicz GM, Czarna A, Wolf S et al (2010) Structures of low molecular weight inhibitors bound to MDMX and MDM2 reveal new approaches for p53-MDMX/MDM2 antagonist drug discovery. Cell Cycle 9:1104–1111
Popowicz GM, Domling A, Holak TA (2011) The structure-based design of Mdm2-p53 inhibitors gets serious. Angew Chem Int Ed Engl 50:2680–2688
Uhrinova S, Uhrin D, Powers H et al (2005) Structure of free MDM2 N-terminal domain reveals conformational adjustments that accompany p53-binding. J Mol Biol 350:587–598
Tovar C, Rosinski J, Filipovic Z et al (2006) Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: implications for therapy. Proc Natl Acad Sci USA 103:1888–1893
Shangary S, Qin D, McEachern D et al (2008) Temporal activation of p53 by a specific MDM2 inhibitor is selectively toxic to tumors and leads to complete tumor growth inhibition. Proc Natl Acad Sci USA 105:3933–3938
Weber L (2010) Patented inhibitors of p53-Mdm2 interaction (2006–2008). Expert Opin Ther Patents 20:179–191
Cheok CF, Verma CS, Baselga J, Lane DP (2011) Translating p53 into the clinic. Nat Rev Clin Oncol 8:25–37
Youle RJ, Strasser A (2008) The BCL-2 protein family: opposing activities that mediate cell death. Nat Rev Mol Cell Biol 9:47–59
Petros AM, Nettesheim DG, Wang Y et al (2000) Rationale for Bcl-x(L)/bad peptide complex formation from structure, mutagenesis, and biophysical studies. Protein Sci 9:2528–2534
Oltersdorf T, Elmore SW, Shoemaker AR et al (2005) An inhibitor of Bcl family proteins induces regression of solid tumours. Nature 435:677–681
Lee EF, Czabotar PE, Smith BJ et al (2007) Crystal structure of ABT-737 complexed with Bcl-xL: implications for selectivity of antagonists of the Bcl-2 family. Cell Death Differ 14:1711–1713
Park C-M, Bruncko M, Adickes J et al (2008) Discovery of an orally bioavailable small-molecule inhibitor of prosurvival B-cell lymphoma 2 proteins. J Med Chem 51:6902–6915
Palladino MA, Bahjat FR, Theodorakis EA, Moldawer LL (2003) Anti-TNF-α therapies: the next generation. Nat Rev Drug Discov 2:736–746
Eck ME, Sprang SR (1989) The structure of tumor necrosis factor-α at 2.6 Å resolution. J Biol Chem 264:17595–17605
He MM, Smith AS, Oslb JD et al (2005) Small-molecule inhibition of TNF-α. Science 310:1022–1025
Debnath AK (2006) Prospects and strategies for the discovery and development of small-molecule inhibitors of six-helix bundle formation in class 1 viral fusion proteins. Curr Opin Investig Drugs 7:118–127
Debnath A (2006) Progress in identifying peptides and small-molecule inhibitors targeted to gp41 of HIV-1. Expert Opin Investig Drugs 15:465–478
Koszalka GW, Meanwell NA (2006) Inhibition of virus entry: an antiviral mechanism of emerging prominence. Curr Opin Investig Drugs 7:106–108
Roymans D, De Bondt HL, Arnoult E et al (2010) Binding of a potent small-molecule inhibitor of six-helix bundle formation requires interactions with both heptad-repeats of the RSV fusion protein. Proc Natl Acad Sci USA 107:308–313
Pawson T, Scott JD (1997) Signaling through scaffold, anchoring, and adaptor proteins. Science 278:2075–2080
Shimaoka M, Springer TA (2003) Therapeutic antagonists and conformational regulation of integrin function. Nat Rev Drug Discov 2:703–716
Scarborough RM, Gretler DD (2000) Platelet glycoprotein IIb-IIIa antagonists as prototypical integrin blockers: novel parenteral and potential oral antithrombotic agents. J Med Chem 43:3453–3473
Takada Y, Ye X, Simon S (2007) The integrins. Genome Biol 8:215
Duggan ME, Hutchinson JH (2000) Ligands to the integrin receptor αvβ3. Expert Opin Ther Patents 10:1367–1383
Cox D, Brennan M, Moran N (2010) Integrins as therapeutic targets: lessons and opportunities. Nat Rev Drug Discov 9:804–820
Cox D (2004) Oral GPIIb/IIIa antagonists: what went wrong? Curr Pharm Des 10:1587–1596
Auzzas L, Zanardi F, Battistini L et al (2010) Targeting αvβ3 integrin: design and applications of mono- and multifunctional RGD-based peptides and semipeptides. Curr Med Chem 17:1255–1299
Xiong JP, Stehle T, Diefenbach B et al (2001) Crystal structure of the extracellular segment of integrin αvβ3. Science 294:339–345
Xiong JP, Stehle T, Zhang R et al (2002) Crystal structure of the extracellular segment of integrin αvβ3 in complex with an arg-gly-asp ligand. Science 296:151–155
Springer TA, Zhu J, Xiao T (2008) Structural basis for distinctive recognition of fibrinogen γC peptide by the platelet integrin αIIbβ3. J Cell Biol 182:791–800
Polman CH, O’Connor PW, Havrdova E et al (2006) A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. New Engl J Med 354:899–910
Targan SR, Feagan BG, Fedorak RN et al (2007) Natalizumab for the treatment of active Crohn’s disease: results of the ENCORE trial. Gastroenterology 132:1672–1683
Tilley JW (2008) Very late antigen-4 integrin antagonists. Expert Opin Ther Patents 18:841–859
Muro F, Iimura S, Sugimoto Y et al (2009) Discovery of trans-4-[1-[[2,5-dichloro-4-(1-methyl-3-indolylcarboxamide)phenyl]acetyl]-(4 S)-methoxy-(2 S)-pyrrolidinylmethoxy]cyclo-hexanecarboxylic acid: an orally active, selective very late antigen-4 antagonist. J Med Chem 52:7974–7992
Faull RJ, Ginsberg MH (1996) Inside-out signaling through integrins. J Am Soc Nephrol 7:1091–1097
Qin J, Vinogradova O, Plow EF (2004) Integrin bidirectional signaling: a molecular view. PLoS Biol 2:0726–0729
Liu G (2001) Small-molecule antagonists of the LFA-1/ICAM-1 interaction as potential therapeutic agents. Expert Opin Ther Patents 11:1383–1393
Potin D, Launay M, Monatlik F et al (2006) Discovery and development of 5-[(5S,9R)-9-(4-cyanophenyl)-3-(3,5-dichlorophenyl)-1-methyl-2,4-dioxo-1,3,7-triazaspiro[4.4]non-7-ylmethyl]-3-thiophenecarboxylic acid (BMS-587101) – a small-molecule antagonist of leukocyte function associated antigen-1. J Med Chem 49:6946–6949
Kallen J, Welzenbach K, Ramage P et al (1999) Structural basis for LFA-1 inhibition upon lovastatin binding to the CD11a I-domain. J Mol Biol 292:1–9
Shimaoka M, Salas A, Yang W et al (2003) Small-molecule integrin antagonists that bind to the β2 subunit I-like domain and activate signals in one direction and block them in the other. Immunity 19:391–402
Welzenbach K, Hommel U, Weitz-Schmidt G (2002) Small-molecule inhibitors induce conformational changes in the I domain and the I-like domain of lymphocyte function associated antigen-1. Molecular insights into integrin inhibition. J Biol Chem 277:10590–10598
Miller MW, Basra S, Kulp DW et al (2009) Small-molecule inhibitors of integrin α2β1 that prevent pathological thrombus formation via an allosteric mechanism. Proc Natl Acad Sci USA 106:719–724
Choi S, Vilaire G, Marcinkiewicz C et al (2007) Small-molecule inhibitors of integrin α2β1. J Med Chem 50:5457–5462
Russell RB, Breed J, Barton GJ (1992) Conservation analysis and structure prediction of the SH2 family of phosphotyrosine binding domains. FEBS Lett 304:15–20
Kasembeli MM, Xu X, Tweardy DJ (2009) SH2 domain binding to phosphopeptide ligands: potential for drug targeting. Front Biosci 14:1010–1022
Gan W, Roux B (2009) Binding specificity of SH2 domains: insight from free energy simulations. Proteins 74:996–1007
Songyang Z, Shoelson SE, Chaudhuri M et al (1993) Sh2 domains recognize specific phosphopeptide sequences. Cell 72:767–778
Songyang Z, Oelson SE, McGlade J et al (1994) Specific motifs recognized by the sh2 domains of csk, 3bp2, fps/fes, grb-2, hcp, shc, syk, and vav. Mol Cell Biol 14:2777–2785
Campbell SJ, Jackson RM (2003) Diversity in the SH2 domain family phosphotyrosyl peptide binding site. Protein Eng 16:217–227
Sawyer TK, Bohacek RS, Dalgarno DC et al (2002) Src homology-2 inhibitors: peptidomimetic and nonpeptide. Mini Rev Med Chem 2:475–488
Lu XL, Cao X, Liu XY, Jiao BH (2010) Recent progress of Src SH2 and SH3 inhibitors as anticancer agents. Curr Med Chem 17:1117–1124
Shakespeare WC (2001) SH2 domain inhibition: a problem solved? Curr Opin Chem Biol 5:409–415
Violette SM, Guan W, Bartlett C et al (2001) Bone-targeted Src SH2 inhibitors block Src cellular activity and osteoclast-mediated resorption. Bone 28:54–64
Shakespeare W, Yang M, Bohacek R (2001) Structure-based design of an osteoclast-selective, nonpeptide Src homology 2 inhibitor with in vivo antiresorptive activity. Proc Natl Acad Sci USA 97:9373–9378
Shakespeare WC, Metcalf CA III, Wang Y et al (2003) Novel bone-targeted Src tyrosine kinase inhibitor drug discovery. Curr Opin Drug Discov Dev 6:729–741
Lange G, Lesuisse D, Deprez P et al (2003) Requirements for specific binding of low affinity inhibitor fragments to the SH2 domain of pp 60Src are identical to those for high affinity binding of full length inhibitors. J Med Chem 46:5184–5195
Garcia-Echeverria C, Furet P, Gay B et al (1998) Potent antagonists of the SH2 domain of Grb2: optimization of the X+1 position of 3-amino-Z-Tyr(PO3H2)-X+1-Asn-NH2. J Med Chem 41:1741–1744
Schoepfer J, Fretz H, Gay B et al (1999) Highly potent inhibitors of the Grb2-SH2 domain. Bioorg Med Chem Lett 9:221–226
Gay B, Suarez S, Caravatti G et al (1999) Selective Grb2 inhibitors as anti-Ras therapy. Cell 83:235–241
Yao ZJ, Richter CR, Cao T et al (1999) Potent inhibition of Grb2 SH2 domain binding by non-phosphate-containing ligands. J Med Chem 42:25–35
Gao Y, Luo J, Yao ZJ et al (2000) Inhibition of Grb2 SH2 domain binding by non-phosphate-containing ligands. 2. 4-(2-Malonyl)phenylalanine as a potent phosphotyrosyl mimetic. J Med Chem 43:911–920
Park IH, Li C (2009) Characterization of molecular recognition of STAT3 SH2 domain inhibitors through molecular simulation. J Mol Recognit 24:254–265
Huang N, Nagarsekar A, Xia G et al (2004) Identification of non-phosphate-containing small molecular weight inhibitors of the tyrosine kinase p56 Lck SH2 domain via in silico screening against the pY+3 binding site. J Med Chem 47:3502–3511
Hung AY, Sheng M (2002) PDZ domains: structural modules for protein complex assembly. J Biol Chem 277:5699–5702
Harris BZ, Lim WA (2001) Mechanism and role of PDZ domains in signaling complex assembly. J Cell Sci 114:3219–3231
Tonikian R, Zhang Y, Sazinsky SL et al (2008) A specificity map for the PDZ domain family. PLoS Biol 6:e239
Stiffler MA, Chen JR, Grantcharova VP et al (2007) PDZ domain binding selectivity is optimized across the mouse proteome. Science 317:364–369
Doyle DA, Lee A, Lewis J et al (1996) Crystal structures of a complexed and peptide-free membrane protein-binding domain: molecular basis of peptide recognition by PDZ. Cell 85:106–1076
Kurakin A, Swistowski A, Wu SC, Bredesen DE (2007) The PDZ domain as a complex adaptive system. PLoS One 2:e953
Ducki S, Bennett E (2009) Protein-protein interactions: recent progress in the development of selective PDZ inhibitors. Curr Chem Biol 3:146–158
Wong HC, Bourdelas A, Krauss A et al (2003) Direct binding of the PDZ domain of dishevelled to a conserved internal sequence in the C-terminal region of Frizzled. Mol Cell 12:1251–1260
Zhang Y, Appleton BA, Wiesmann C et al (2009) Inhibition of Wnt signaling by dishevelled PDZ peptides. Nat Chem Biol 5:217–219
Fujiu N, You L, Xu Z et al (2007) An antagonist of dishevelled protein-protein interaction suppresses β-catenin-dependent tumor cell growth. Cancer Res 67:573–579
Grandy D, Shan J, Zhang X et al (2009) Discovery and characterization of a small-molecule inhibitor of the PDZ domain of dishevelled. J Biol Chem 284:16256–16263
Lee HJ, Wang NX, Shi DL, Zheng JJ (2009) Sulindac inhibits canonical Wnt signaling by blocking the PDZ domain of the protein dishevelled. Angew Chem Int Ed Engl 48:6448–6452
Gyrd-Hansen M, Meier P (2010) IAPs: from caspase inhibitors to modulators of NF-kB, inflammation and cancer. Nat Rev Cancer 10:561–574
Srinivasula SM, Hegde R, Saleh A et al (2001) A conserved XIAP-interaction motif in caspase-9 and Smac/DIABLO regulates caspase activity and apoptosis. Nature 410:112–116
Shiozaki EN, Chai J, Rigotti DJ et al (2003) Mechanism of XIAP-mediated inhibition of caspase-9. Mol Cell 11:519–527
Du C, Fang M, Li Y et al (2000) Smac, a mitochondrial protein that promotes cytochrome c-dependent caspase activation by eliminating IAP inhibition. Cell 102:33–42
Verhagen AM, Ekert PG, Pakusch M et al (2000) Identification of DIABLO, a mammalian protein that promotes apoptosis by binding to and antagonizing IAP proteins. Cell 102:43–53
Liu Z, Sun C, Olejniczak ET et al (2000) Structural basis for binding of Smac/DIABLO to the XIAP BIR3 domain. Nature 408:1004–1008
Wu G, Chai J, Suber TL et al (2000) Structural basis of IAP recognition by Smac/DIABLO. Nature 408:1008–1012
Chai J, Du C, Wu JW et al (2000) Structural and biochemical basis of apoptotic activation by Smac/DIABLO. Nature 406:855–862
Kipp RA, Case MA, Wist AD et al (2002) Molecular targeting of inhibitors of apoptosis proteins based on small-molecule mimics of natural binding partners. Biochemistry 41:7344–7349
Zobel K, Wang L, Varfolomeev E et al (2006) Design, synthesis, and biological activity of a potent Smac mimetic that sensitizes cancer cells to apoptosis by antagonizing IAPs. ACS Chem Biol 1:525–534
Peng Y, Sun H, Nikolovska-Coleska Z et al (2008) Design, synthesis and evaluation of potent and orally bioavailable diazabicyclic smac mimetics. J Med Chem 51:8158–8162
Sun H, Stuckey JA, Nikolovska-Coleska Z et al (2008) Structure-based design, synthesis, evaluation and crystallographic studies of conformationally constrained Smac mimetics as inhibitors of the X-linked inhibitor of apoptosis protein (XIAP). J Med Chem 51:7169–7180
Oost TK, Sun C, Armstrong RC et al (2004) Discovery of potent antagonists of the antiapoptotic protein XIAP for the treatment of cancer. J Med Chem 47:4417–4426
Park CM, Sun C, Olejniczak ET et al (2005) Non-peptidic small-molecule inhibitors of XIAP. Bioorg Med Chem Lett 15:771–775
Chauhan D, Neri P, Velankar M et al (2007) Targeting mitochondrial factor Smac/DIABLO as therapy for multiple myeloma (MM). Blood 109:1220–1227
Gaither A, Porter D, Yao Y et al (2007) A Smac mimetic rescue screen reveals roles for inhibitor of apoptosis proteins in tumor necrosis factor-alpha signaling. Cancer Res 67:11493–11498
Huang Y, Rich RL, Myszka DG, Wu H (2003) Requirement of both the second and third BIR domains for the relief of X-linked inhibitor of apoptosis protein (XIAP)-mediated caspase inhibition by Smac. J Biol Chem 278:49517–49522
Li L, Thomas RM, Suzuki H et al (2004) A small-molecule smac mimic potentiates TRAIL- and TNF-α-mediated cell death. Science 305:1471–1474
Bertrand MJ, Milutinovic S, Dickson KM et al (2008) cIAP1 and cIAP2 facilitate cancer cell survival by functioning as E3 ligases that promote RIP1 ubiquitination. Mol Cell 30:689–700
Sun H, Nikolovska-Coleska Z, Lu J et al (2007) Design, synthesis and characterization of a potent, nonpeptide, cell-permeable, bivalent smac mimetic that concurrently targets both the BIR2 and BIR3 domains in XIAP. J Am Chem Soc 129:15279–15294
Nikolovska-Coleska Z, Meagher JL, Jiang S et al (2008) Interaction of a cyclic, bivalent Smac mimetic with the X-linked inhibitor of apoptosis protein. Biochemistry 47:9811–9824
Sun C, Cai M, Meadows RP et al (2000) NMR structure and mutagenesis of the third BIR domain of the inhibitor of apoptosis protein XIAP. J Biol Chem 275:33777–33781
Cherepanov P, Sun ZYJ, Rahman S et al (2005) Solution structure of the HIV-1 integrase-binding domain in LEDGF/p75. Nat Struct Mol Biol 12:526–532
Cherepanov P, Ambrosio ALB, Rahman S et al (2005) Structural basis for the recognition between HIV-1 integrase and transcriptional coactivator p75. Proc Natl Acad Sci USA 102:17308–17313
Maertens G, Cherepanov P, Pluymers W et al (2003) LEDGF/p75 is essential for nuclear and chromosomal targeting of HIV-1 integrase in human cells. J Biol Chem 278:33528–33539
Christ F, Voet A, Marchand A et al (2010) Rational design of small-molecule inhibitors of the LEDGF/p75-integrase interaction and HIV replication. Nat Chem Biol 6:442–448
Du L, Zhao Y, Chen J et al (2008) D77, one benzoic acid derivative, functions as a novel anti-HIV-1 inhibitor targeting the interaction between integrase and cellular LEDGF/p75. Biochem Biophys Res Commun 375:139–144
De Luca L, Barreca ML, Ferro S et al (2009) Pharmacophore-based discovery of small-molecule inhibitors of protein-protein interactions between HIV-1 integrase and cellular cofactor LEDGF/p75. ChemMedChem 4:1311–1316
De Luca L, Ferro S, Gitto R et al (2010) Small molecules targeting the interaction between HIV-1 integrase and LEDGF/p75 cofactor. Bioorg Med Chem 18:7515–7521
Dey A, Chitsaz F, Abbasi A et al (2003) The double bromodomain protein Brd4 binds to acetylated chromatin during interphase and mitosis. Proc Natl Acad Sci USA 100:8758–8763
Wu SY, Lee AY, Hou SY et al (2006) Brd4 links chromatin targeting to HPV transcriptional silencing. Genes Dev 20:2383–2396
Wu SY, Chiang CM (2007) The double bromodomain-containing chromatin adaptor Brd4 and transcriptional regulation. J Biol Chem 282:13141–13145
Liu Y, Wang X, Zhang J et al (2008) Structural basis and binding properties of the second bromodomain of Brd4 with acetylated histone tails. Biochemistry 47:6403–6417
Vollmuth F, Blankenfeldt W, Geyer M (2009) Structures of the dual bromodomains of the P-TEFb-activatin protein Brd4 at atomic resolution. J Biol Chem 284:36547–36556
Myoshi S, Ooike S, Iwata K et al (2009) Antitumor agent. PCT Int Appl WO2009084693
Filippakopoulos P, Qi J, Picaud S et al (2010) Selective inhibition of BET bromodomains. Nature 468:1067–1073
Mertz JA, Conery AR, Bryant BM et al (2011) Targeting MYC dependence in cancer by inhibiting BET bromodomains. Proc Natl Acad Sci USA 108:16669–16674
Delmore JE, Issa GC, Lemieux ME et al (2011) BET bromodomain inhibition as a therapeutic strategy to target c-myc. Cell 146:904–917
Chung C, Coste H, White JH et al (2011) Discovery and characterization of small-molecule inhibitors of the BET family bromodomains. J Med Chem 54:3827–3838
Nicodeme E, Jeffrey KL, Schaefer U et al (2010) Suppression of inflammation by a synthetic histone mimic. Nature 468:1119–1123
Dawson MA, Prinjha RK, Dittman A et al (2011) Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia. Nature 478:529–533
Muller S, Filippakopoulos P, Knapp S (2011) Bromodomains as therapeutic targets. Expert Rev Mol Med 13:e29
Chung C, Witherington J (2011) Progress in the discovery of small-molecule inhibitors of bromodomain-histone interactions. J Biomol Screen 16:1170–1185
Chung C, Dean AW, Woolven JM, Bamborough P (2012) Fragment-based discovery of bromodomain inhibitors part 1: inhibitor binding modes and implications for lead discovery. J Med Chem 55:576–586
Acknowledgments
The author is grateful to Kent Stewart for reading and offering comments on the manuscript.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2012 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Wendt, M.D. (2012). Protein-Protein Interactions as Drug Targets. In: Wendt, M. (eds) Protein-Protein Interactions. Topics in Medicinal Chemistry, vol 8. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-28965-1_1
Download citation
DOI: https://doi.org/10.1007/978-3-642-28965-1_1
Published:
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-28964-4
Online ISBN: 978-3-642-28965-1
eBook Packages: Chemistry and Materials ScienceChemistry and Material Science (R0)